



**Planet Depos**<sup>®</sup>  
We Make It *Happen*<sup>™</sup>

---

**CONFIDENTIAL - UNDER PROTECTIVE ORDER**

# Transcript of Irene Loeffler

**Date:** May 1, 2018

**Case:** Pfizer, Inc. -v- Genentech, Inc. (PTAB)

**Planet Depos**

**Phone:** 888.433.3767

**Email:** [transcripts@planetdepos.com](mailto:transcripts@planetdepos.com)

**www.planetdepos.com**

WORLDWIDE COURT REPORTING | INTERPRETATION | TRIAL SERVICES

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

<p>1 UNITED STATES PATENT AND TRADEMARK OFFICE                  2 -----                  3 BEFORE THE PATENT TRIAL AND APPEAL BOARD                  4 -----                  5 PFIZER, INC. and SAMSUNG BIOEPIS CO., LTD.,                  6 Petitioner,                  7 v.                  8 GENENTECH, INC.,                  9 Patent Owner.                  10 -----                  11 Case Nos. IPR2017-01488, IPR2017-01489                  12 -----                  13 CELLTRION, INC.,                  14 Petitioner,                  15 v.                  16 GENENTECH, INC.,                  17 Patent Owner.                  18 -----                  19 Case Nos. IPR2017-01373, IPR2017-01374                  20                  21 ** CONFIDENTIAL - UNDER PROTECTIVE ORDER **                  22 VIDEOTAPED DEPOSITION OF IRENE LOEFFLER                  23 San Francisco, California                  24 Tuesday, May 1, 2018                  25 12:59 p.m.</p>	<p>1 A P P E A R A N C E S                  2 ON BEHALF OF PETITIONER PFIZER, INC.:                  3 SHARICK NAQI, ESQUIRE                  4 BENJAMIN LASKY, ESQUIRE                  5 KIRKLAND &amp; ELLIS, LLP                  6 300 North LaSalle                  7 Chicago, Illinois 60654                  8 (312) 861-2000                  9 ON BEHALF OF PETITIONER CELLTRION:                  10 LINNEA P. CIPRIANO, ESQUIRE                  11 (Via videoconference)                  12 GOODWIN PROCTER LLP                  13 620 Eighth Avenue                  14 New York, New York 10019                  15 (212) 813-8800                  16 ON BEHALF OF PATENT OWNER GENENTECH, INC.:                  17 ANDREW J. DANFORD, ESQUIRE                  18 NORA Q.E. PASSAMANECK, ESQUIRE                  19 WILMER CUTLER PICKERING HALE AND DORR, LLP                  20 60 State Street,                  21 Boston, Massachusetts 02109                  22 (617) 526-6022                  23 ALSO PRESENT:                  24 Joseph A. Mourgos, Videographer                  25 Traci Ropp, Genentech</p>
<p>1 Job No.: 186258                  2 Pages: 1 - 52                  3 Reported By: Charlotte Lacey, RPR, CSR No. 14224                  4                  5                  6 VIDEOTAPED DEPOSITION OF IRENE LOEFFLER, held at                  7 the offices of DURIE TANGRI, 217 Leidesdorff Street,                  8 San Francisco, California                  9                  10                  11                  12 Pursuant to notice, before Charlotte Lacey,                  13 Certified Shorthand Reporter, in and for the State of                  14 California.                  15                  16                  17                  18                  19                  20                  21                  22                  23                  24                  25</p>	<p>1 I N D E X                  2 WITNESS PAGE                  3 IRENE LOEFFLER                  4 Examination by Mr. Naqi 10                  5 Examination by Mr. Danford 39                  6                  7                  8 I N D E X O F E X H I B I T S                  9 EXHIBITS DESCRIPTION PAGE                  10 (None offered)                  11                  12 P R E V I O U S L Y M A R K E D E X H I B I T S                  13 EXHIBIT DESCRIPTION PAGE                  14 Exhibit 2001 Copy of laboratory notebook 13                  15 number 10098 (retained by deponent)                  16 Exhibit 2002 Copy of laboratory notebook 13                  17 number 10823 (retained by deponent)                  18 Exhibit 2003 Copy of laboratory notebook 13                  19 number 11268 (retained by deponent)                  20 Exhibit 2004 Copy of laboratory notebook 13                  21 number 11643 (retained by deponent)                  22 Exhibit 2005 Copy of laboratory notebook 13                  23 number 10840 (retained by deponent)                  24 Exhibit 2006 Copy of laboratory notebook 13                  25 number 11162 (retained by deponent)</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

CONFIDENTIAL - UNDER PROTECTIVE ORDER

Transcript of Irene Loeffler

2 (5 to 8)

Conducted on May 1, 2018

<p>5</p> <p>1 Exhibit 2007 Copy of laboratory notebook 13</p> <p>2 number 11008 (retained by deponent)</p> <p>3 Exhibit 2008 Copy of laboratory notebook 13</p> <p>4 number 11297 (retained by deponent)</p> <p>5 Exhibit 2009 Copy of laboratory notebook 13</p> <p>6 number 11568 (retained by deponent)</p> <p>7 Exhibit 2019 Declaration of Irene Loeffler in 12</p> <p>8 case number IPR2017-01488 (retained</p> <p>9 by deponent)</p> <p>10 Exhibit 2019 Declaration of Irene Loeffler in 12</p> <p>11 case number IPR2017-01489 (retained</p> <p>12 by deponent)</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p>7</p> <p>1 MS. CIPRIANO: Linnea Cipriano with Goodwin</p> <p>2 Procter representing Celltrion.</p> <p>3 THE VIDEOGRAPHER: Thank you.</p> <p>4 The court reporter today is Charlotte Lacey</p> <p>5 representing Planet Depos.</p> <p>6 Would the reporter please administer the oath.</p> <p>7 IRENE LOEFFLER,</p> <p>8 the witness herein, having been first duly sworn, was</p> <p>9 examined and testified as follows:</p> <p>10 MR. LASKY: Before we get started, I'm going</p> <p>11 to state an objection on the record. During a break in</p> <p>12 the earlier deposition of Len Presta, we were informed</p> <p>13 for the first time that counsel had brought today what</p> <p>14 he said were the microfilmed versions of various</p> <p>15 documents, notebooks that had been presented as</p> <p>16 exhibits -- as exhibits by Genentech in this case.</p> <p>17 At a subsequent break, 12:15, for the first</p> <p>18 time, counsel put those microfilmed versions in front of</p> <p>19 us. There are hundreds of pages of documents there. We</p> <p>20 object to the extent that counsel intends to raise these</p> <p>21 documents today at the deposition. We have not had the</p> <p>22 chance to review them. They have not been submitted as</p> <p>23 exhibits. We were given a very brief time to review</p> <p>24 them. And despite counsel's representation that the</p> <p>25 documents are identical to those that were already</p>
<p>6</p> <p>1 P R O C E E D I N G S</p> <p>2 THE VIDEOGRAPHER: Here begins video number 1</p> <p>3 in the videotaped deposition of Irene Loeffler in the</p> <p>4 matter of Pfizer Incorporated versus Genentech</p> <p>5 Incorporated, IPR number 2017-01488 and 01489, and</p> <p>6 Celltrion versus Genentech, IPR number 2017-01373 and</p> <p>7 01374 in the United States Patent and Trademark Office</p> <p>8 before the Patent Trial and Appeal Board.</p> <p>9 Today's date is May 1st, 2018, and the time on</p> <p>10 the video monitor is 12:59 p.m. The videographer today</p> <p>11 is Joseph Mourgos representing Planet Depos. This video</p> <p>12 deposition is taking place at 217 Leidesdorff Street,</p> <p>13 San Francisco, California.</p> <p>14 Would counsel voice identify yourselves and</p> <p>15 state whom you represent.</p> <p>16 MR. NAQI: My name is Sharick Naqi. I'm from</p> <p>17 Kirkland &amp; Ellis, and I represent Pfizer. And with me</p> <p>18 today is my colleague, Benjamin Lasky, also from</p> <p>19 Kirkland &amp; Ellis.</p> <p>20 MR. DANFORD: My name is Andrew Danford from</p> <p>21 WilmerHale, and I represent Genentech and the witness.</p> <p>22 And I'm joined today by my colleague Nora Passamaneck of</p> <p>23 WilmerHale and Traci Ropp of Genentech.</p> <p>24 THE VIDEOGRAPHER: And on the telephone, we</p> <p>25 have...</p>	<p>8</p> <p>1 produced, just in the half an hour we've had a chance to</p> <p>2 review them today, we've already found at least three</p> <p>3 differences between the microfilmed versions and the</p> <p>4 produced -- the versions that were produced to us.</p> <p>5 And so we object to the use of these documents</p> <p>6 during the deposition today. We object to their use in</p> <p>7 these proceedings as a whole.</p> <p>8 MR. DANFORD: I object to that colloquy. I</p> <p>9 mean, as I understand it, Mr. Naqi's taking the</p> <p>10 deposition here today, and you're in the second chair.</p> <p>11 So -- that's for starters.</p> <p>12 I also say we gave you sufficient time for</p> <p>13 this. If you want to ask about the microfilms, you're</p> <p>14 welcome to do so. We are not pressuring you to go</p> <p>15 forward with this right now. You could have taken as</p> <p>16 much time as you wanted to review those. There have</p> <p>17 been questions raised in these proceedings about the</p> <p>18 microfilms. There is no difference, from our</p> <p>19 perspective, from the lab notebooks that have been</p> <p>20 produced and the microfilms, and so we're making them</p> <p>21 available to you now in case you had any questions about</p> <p>22 them.</p> <p>23 MR. LASKY: Mr. Danford, the issues of</p> <p>24 microfilms have been -- have been raised since at least</p> <p>25 Dr. Carter's deposition and possibly even before, and</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

9	<p>1 that was days ago. There's no reason why this couldn't                  2 have been raised earlier. Frankly, there's no reason                  3 why this couldn't have been produced when the exhibits                  4 were produced in the first place. I can demonstratively                  5 prove to you that there are differences between the                  6 microfilms versions and the versions that were produced                  7 to us.                  8 We were not given time to review these today.                  9 We're here sitting in San Francisco where we've traveled                  10 for this deposition, and we have not had more than half                  11 an hour to review this. It was raised -- I don't even                  12 know why it wasn't raised earlier during Dr. Presta's                  13 deposition, why you had to wait till the second                  14 five-minute break that we received.                  15 And as for the fact that I'm not taking this                  16 deposition, you raised these documents first during the                  17 deposition of Dr. Presta, and as you're well aware, my                  18 colleague and I share in the duties today.                  19 MR. DANFORD: Well --                  20 MS. CIPRIANO: And if I can note for the                  21 record that Celltrion has not been produced -- they have                  22 not been provided an opportunity to review these                  23 documents. They were given a hard copy, and I am                  24 attending the deposition electronically.                  25 MR. DANFORD: Okay.</p>	11	<p>1 <b>A Verifying lab notebooks at Genentech; previous</b>                  2 <b>jobs, previous documents.</b>                  3 Q And were these patent matters?                  4 <b>A At Genentech?</b>                  5 Q Yes.                  6 <b>A I -- I don't really remember the nature of the</b>                  7 <b>case.</b>                  8 Q You are currently employed at Genentech; is                  9 that right?                  10 <b>A Yes.</b>                  11 Q What is your current title at Genentech?                  12 <b>A Associate Director.</b>                  13 Q In general, what is your role in that                  14 position?                  15 <b>A Records management.</b>                  16 Q And could you elaborate on that?                  17 <b>A Specifically for the case, we're talking about</b>                  18 <b>laboratory notebooks, so I oversee the issuing,</b>                  19 <b>tracking, recalling, scanning, indexing, and retrieving</b>                  20 <b>lab notebooks of their images.</b>                  21 Q And what was your title at Genentech in 1989?                  22 <b>A Whatever it said in my deposition. I don't</b>                  23 <b>remember the exact title at that time.</b>                  24 Q And what was your role in 1989?                  25 <b>A Records. It's been records my entire career.</b></p>
10	<p>1 MS. CIPRIANO: And we add, for the record, we                  2 have the same objections as Mr. Lasky.                  3 MR. DANFORD: All right. Your objections have                  4 been noted. Let's see where this goes.                  5 EXAMINATION                  6 BY MR. NAQI:                  7 Q Good morning.                  8 <b>A Good morning.</b>                  9 Q Would you please state your full name for the                  10 record.                  11 <b>A Irene Loeffler.</b>                  12 Q Ms. Loeffler, have you had your deposition                  13 taken before?                  14 <b>A Yes.</b>                  15 Q How many times?                  16 <b>A In my life, maybe four or five.</b>                  17 Q And when was the first time you were deposed?                  18 <b>A Previous employment, back in the -- probably</b>                  19 <b>early '80s.</b>                  20 Q And your subsequent depositions, were they all                  21 related to your work at Genentech?                  22 <b>A As I recall, I had perhaps two at my previous</b>                  23 <b>employment and maybe two or three at Genentech.</b>                  24 Q And what was the subject matter of these                  25 depositions?</p>	12	<p>1 Q So was it similar to your current role?                  2 <b>A I've been promoted a few times, so I have more</b>                  3 <b>responsibilities as time went on.</b>                  4 Q I've just handed you two documents. The first                  5 document has been marked as Exhibit 2019 in                  6 IPR2017-01488 and the other one has been marked as                  7 Exhibit 2019 in IPR2017-01489.                  8 Have you seen these documents before?                  9 <b>A Yes.</b>                  10 Q And are these declarations that you have                  11 submitted in proceedings regarding U.S. patent                  12 number 6,407,213?                  13 <b>A Yes.</b>                  14 Q Is it fair to say that these two declarations                  15 are substantively identical in terms of their contents?                  16 <b>A Yes.</b>                  17 Q And to the extent that declarations were                  18 submitted from you in multiple proceedings involving                  19 Pfizer and Celltrion, they would be copies of the same                  20 declaration?                  21 <b>A Yes.</b>                  22 Q And to the extent I ask you questions about                  23 one of these, would your answers apply equally to the                  24 other declarations as well?                  25 <b>A Yes.</b></p>

<p>1 Q Did you review your declaration in preparation 2 for this deposition? 3 <b>A Yes.</b> 4 Q Was there anything in there that you saw that 5 was incorrect? 6 <b>A No.</b> 7 Q Is there anything in there that you saw that 8 would change if you could write it again? 9 <b>A No.</b> 10 Q Let's turn to page 1 of your declaration. You 11 can use the one marked for -- 1488. Do you see it -- 12 the proceedings. 13 So at paragraph 4 on page 1 of your 14 declaration, do you see the first sentence that says, 15 "The exhibits listed below are true and authentic copies 16 of several Genentech laboratory notebooks"? 17 <b>A Yes.</b> 18 Q Now, you're referring to the Genentech 19 Exhibits 2001 through 2009 listed in paragraph 4 of your 20 declaration; is that correct. 21 <b>A Yes.</b> 22 Q Now, do you know how the -- how the copies 23 that you referred to in paragraph 4, first sentence of 24 your declaration were made? 25 MR. DANFORD: Objection to form.</p>	<p>13</p> <p>1 Q So Genentech Exhibits 2001 through 2009 are 2 the high-resolution, color-scanned copies made from the 3 physical notebooks in 2016; is that correct? 4 <b>A Right.</b> 5 Q And separate copies of these notebooks were 6 also made early earlier in the 1990s using microfilm 7 technology? 8 <b>A Right.</b> 9 Q Now, you have not presented the microfilm 10 versions of these notebooks made early in '90 -- in 11 1990s in your declaration. 12 <b>A The declaration pertained to the scanned ones.</b> 13 Q So let's turn to page 6 of your declaration 14 starting at the first sentence. I'm sorry. Paragraph 6 15 of your declaration starting at the first sentence. 16 There, you state, "I am familiar with 17 Genentech's practices regarding the creation, 18 modification, and keeping of its laboratory notebooks 19 through my employment at Genentech." 20 <b>A Right.</b> 21 Q "Each of the laboratory notebooks listed above 22 was created by Genentech personnel during the regular 23 course of business." 24 <b>A Right.</b> 25 Q And then you state, "It was the regular</p>
<p>1 <b>A I'm sorry?</b> 2 MR. DANFORD: I just objected to the form of 3 the question. 4 Q You can answer. 5 MR. DANFORD: If you understand it. 6 <b>A Yeah. So the copies had been scanned, and 7 then I believe what you have now are printouts.</b> 8 Q And when were these copies scanned? 9 <b>A They were on or around the time of the 10 declaration.</b> 11 Q Now, on -- and when was that declaration 12 prepared? 13 <b>A August 4th, 2017.</b> 14 Q So Exhibits 2001 through 2009 are copies that 15 were scanned from the actual notebooks in August 2017; 16 is that correct? 17 <b>A I--</b> 18 MR. DANFORD: Objection; lacks foundation. 19 <b>A I don't know exactly when they were scanned, 20 but, yes, they were scanned from the original lab 21 notebooks.</b> 22 Q Maybe I can help you. If you turn to page 3 23 of your declaration, paragraph 7, last sentence. 24 Do you see where it says -- 25 <b>A Okay. So around November 2016.</b></p>	<p>14</p> <p>1 practice of Genentech's personnel to create such records 2 at or near the time the recorded act, event, condition, 3 or opinion occurred." 4 <b>A Right.</b> 5 Q And then you state -- and you state, "It was 6 the general practice of Genentech's personnel to date 7 such documents as of the date the record was 8 modified" -- I'm sorry -- "was created or modified." 9 <b>A Right.</b> 10 Q So here in paragraph 6, you're discussing the 11 regular practice of Genentech's personnel or the general 12 practice of -- of Genentech's personnel; is that 13 correct? 14 <b>A Yes.</b> 15 Q Do you have any knowledge about the practice 16 of any particular Genentech employee in terms of making 17 entries into these notebooks? 18 MR. DANFORD: Objection to form. 19 <b>A No.</b> 20 Q So you don't have any personal knowledge about 21 how each one of these notebooks was filled in. 22 <b>A No.</b> 23 Q And in the last sentence of paragraph 6, you 24 state, "Such records would only be made by someone with 25 knowledge or from information transmitted by someone</p>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.